An interventional study of Remedy Robot in Cerebrovascular Disease, sponsored by Remedy Robotics, Inc.. Status unknown. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-04-15.
Sponsored by Remedy Robotics, Inc. · Not applicable, Interventional, and Device feasibility
This study is a prospective, single arm, single-center study to evaluate the safety and feasibility of the Remedy Robot for on premise and remote robotic Neurointervention.
This is a prospective, single-arm, single-center study to evaluate the safety and effectiveness of the Remedy Robot for patients with a clinical indication for Neurointervention.
385 studies on the registry are indexed under Cerebrovascular Disorders; 129 are open to participants now.
This study's planned enrollment of 10 is below the median of 109 across 224 interventional studies indexed under Cerebrovascular Disorders.
Browse Cerebrovascular Disorders studies →This is the only study on the registry with Remedy Robotics, Inc. as lead sponsor.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria:
People with any of the following medical history:
Group undergoing intervention with the Remedy Robot.
Device: Remedy Robot
A trained Neurointerventionalist will operate the Remedy Robot from a computer-based user interface in a room adjacent to the patient. An entire cerebral angiogram or cerebral embolization will be performed, excluding insertion and removal of the femoral sheath.
Procedural safety
Incidence of intra- and peri-procedural events, including all cause mortality, stroke, arterial dissection, arterial perforation
Time frame: Measured from the start of the procedure through 24 hours or discharge
Procedural Technical Success
Successful completion of the robotic-assisted endovascular procedure absent any unplanned conversion to manual control
Time frame: Measured from the start of the procedure through to the completion of the procedure
No study locations are listed for this record.
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Jun 2024; primary completion for Jan 2025, 7 months later.
Of 100 interventional studies with no phase under Cerebrovascular Disorders, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 58. This study's planned 7 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is status unknown, as verified in Apr 2024. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.